Osteoclast differentiation by RANKL and OPG signaling pathways
N Udagawa, M Koide, M Nakamura… - Journal of bone and …, 2021 - Springer
Introduction In bone tissue, bone resorption by osteoclasts and bone formation by
osteoblasts are repeated continuously. Osteoclasts are multinucleated cells that derive from …
osteoblasts are repeated continuously. Osteoclasts are multinucleated cells that derive from …
The regulation of bone metabolism and disorders by Wnt signaling
K Maeda, Y Kobayashi, M Koide, S Uehara… - International journal of …, 2019 - mdpi.com
Wnt, a secreted glycoprotein, has an approximate molecular weight of 40 kDa, and it is a
cytokine involved in various biological phenomena including ontogeny, morphogenesis …
cytokine involved in various biological phenomena including ontogeny, morphogenesis …
[HTML][HTML] Irisin mediates effects on bone and fat via αV integrin receptors
H Kim, CD Wrann, M Jedrychowski, S Vidoni, Y Kitase… - Cell, 2018 - cell.com
Irisin is secreted by muscle, increases with exercise, and mediates certain favorable effects
of physical activity. In particular, irisin has been shown to have beneficial effects in adipose …
of physical activity. In particular, irisin has been shown to have beneficial effects in adipose …
Skeletal aging and osteoporosis: mechanisms and therapeutics
A Chandra, J Rajawat - International journal of molecular sciences, 2021 - mdpi.com
Bone is a dynamic organ maintained by tightly regulated mechanisms. With old age, bone
homeostasis, which is maintained by an intricate balance between bone formation and bone …
homeostasis, which is maintained by an intricate balance between bone formation and bone …
Can we safely target the WNT pathway?
M Kahn - Nature reviews Drug discovery, 2014 - nature.com
WNT–β-catenin signalling is involved in a multitude of developmental processes and the
maintenance of adult tissue homeostasis by regulating cell proliferation, differentiation …
maintenance of adult tissue homeostasis by regulating cell proliferation, differentiation …
[HTML][HTML] Romosozumab in postmenopausal women with low bone mineral density
MR McClung, A Grauer, S Boonen… - … England Journal of …, 2014 - Mass Medical Soc
Background Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The
monoclonal antibody romosozumab binds to sclerostin and increases bone formation …
monoclonal antibody romosozumab binds to sclerostin and increases bone formation …
WNT signaling in bone homeostasis and disease: from human mutations to treatments
R Baron, M Kneissel - Nature medicine, 2013 - nature.com
Low bone mass and strength lead to fragility fractures, for example, in elderly individuals
affected by osteoporosis or children with osteogenesis imperfecta. A decade ago, rare …
affected by osteoporosis or children with osteogenesis imperfecta. A decade ago, rare …
Prevention and treatment of postmenopausal osteoporosis
In the beginning, that is from the 1960's, when a link between menopause and osteoporosis
was first identified; estrogen treatment was the standard for preventing bone loss, however …
was first identified; estrogen treatment was the standard for preventing bone loss, however …
Parathyroid hormone: anabolic and catabolic actions on the skeleton
BC Silva, JP Bilezikian - Current opinion in pharmacology, 2015 - Elsevier
Highlights•Parathyroid hormone has dual anabolic and catabolic actions on the
skeleton.•The OPG–RANKL–RANK pathway is the main mediator of the catabolic actions of …
skeleton.•The OPG–RANKL–RANK pathway is the main mediator of the catabolic actions of …
Osteoporosis: now and the future
TD Rachner, S Khosla, LC Hofbauer - The Lancet, 2011 - thelancet.com
Osteoporosis is a common disease characterised by a systemic impairment of bone mass
and microarchitecture that results in fragility fractures. With an ageing population, the …
and microarchitecture that results in fragility fractures. With an ageing population, the …